Celadon Pharmaceuticals Plc. engages in the research, cultivation, manufacturing and supply of cannabinoid-based medicines. Its focuses on improving quality of life for chronic pain sufferers and exploring the potential of cannabinoid-based medicines for other conditions such as autism. The company was founded in 2018 and is headquartered in London, the United Kingdom.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company